Abstract Using Richardson and Davidson's model and the sciences of pharmacokinetics and
clinical pharmacopsychology, this article reviewed the:(1) poor life expectancy associated …

Introduction Patients with schizophrenia have an elevated mortality risk compared to the
general population, with cardiovascular-related deaths being the leading cause. The role of …

One of the most widely used guides to prescribing psychiatric medications, the Tenth Edition
of Maudsley Prescribing Guidelines returns with fully updated content and new sections on …

Objective: To identify the outcome of potentially serious adverse effects of clozapine,
particularly those frequently cited as reasons for clozapine discontinuation, and to …

Objective We review the published cases of clozapine‐induced myocarditis and describe
reasons for the higher incidence in Australia (> 1%) than elsewhere (< 0.1%). Method …

Objective: This study evaluated rates of all-cause mortality and self-harm in association with
clozapine treatment in individuals with treatment-resistant schizophrenia. Method: A …

Patients with schizophrenia have a higher mortality risk than patients suffering from any
other psychiatric disorder. Previous research is inconclusive regarding the association of …

BackgroundSchizophrenia affects 1% of the population. Clozapine is the only medication
licensed for treatment-resistant schizophrenia and is intensively monitored to prevent harm …

Background Clozapine is uniquely effective in the management of treatment-resistant
schizophrenia (TRS). However, a substantial proportion of patients discontinue treatment …

This study assessed the association between second-generation antipsychotic medications
and risk of pneumonia requiring hospitalization in patients with schizophrenia because the …